Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.

ABSTRACT:

Background

Safinamide is a novel α-aminoamide with dopaminergic and non-dopaminergic properties developed as adjunctive therapy for patients with PD. Results from a 24-month double-blind controlled study suggested that as add-on to levodopa (and other PD medications) the benefits of safinamide on dyskinesia may be related to severity of dyskinesia at baseline.

Objective

This post-hoc analysis further characterized the effects of safinamide on dyskinesia in mid- to late-stage PD patients.

Methods

Patients were stratified by the presence or absence of dyskinesia at baseline, and by whether or not the dose of levodopa had been changed during the 24-month treatment period. Differences between safinamide and placebo were evaluated using the Wilcoxon rank-sum test.

Resul

SUBMITTER: Cattaneo C 

PROVIDER: S-EPMC4923744 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature